Remember when Valeant was counting on a sales force beef-up to revive its struggling GI franchise? It may have just run into a big problem in that department.…

​​​​​​​Big Pharma might not like billionaire John Arnold’s latest move any more than they did his first. After helping cost-effectiveness watchdog ICER get…

When the week began, Stada had plenty of interested suitors, but it wasn’t sure any of them would make a real offer. Now, the first has come in at $3.72…

Allergan CEO Brent Saunders has said it before, and he’ll say it again: He’s not interested in buying Valeant.

Pharma’s top U.S. execs haven’t been shy about expressing their desire for tax reform—and now, they’re taking those wishes directly to Congress.

Pharma execs and boards essentially pressed pause on dealmaking as 2016 came to a close, with uncertainties about the U.S. presidential election—and a Donald…

Bayer’s pharma products have been growing lickety-split, and its 2016 numbers show just how—and how much. But with the big Monsanto merger top of mind at Bayer…

If all baby boomers got tested for hep C, that could help stem freefall of Gilead's blockbusters—and it's exactly the move the company is…

Activist investors have moved in on Bristol-Myers Squibb, including Carl Icahn, who has a long history of pushing drugmakers to put themselves on the block.

Pharma